Literature DB >> 10620501

Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins.

A Goyal1, J K Batra.   

Abstract

Chimaeric toxins have considerable therapeutic potential to treat various malignancies. We have previously used the fungal ribonucleolytic toxin restrictocin to make chimaeric toxins in which the ligand was fused at either the N-terminus or the C-terminus of the toxin. Chimaeric toxins containing ligand at the C-terminus of restrictocin were shown to be more active than those having ligand at the N-terminus of the toxin. Here we describe the further engineering of restrictocin-based chimaeric toxins, anti-TFR(scFv)-restrictocin and restrictocin-anti-TFR(scFv), containing restrictocin and a single chain fragment variable (scFv) of a monoclonal antibody directed at the human transferrin receptor (TFR), to enhance their cell-killing activity. To promote the independent folding of the two proteins in the chimaeric toxin, a linear flexible peptide, Gly-Gly-Gly-Gly-Ser, was inserted between the toxin and the ligand to generate restrictocin-linker-anti-TFR(scFv) and anti-TFR(scFv)-linker-restrictocin. A 12-residue spacer, Thr-Arg-His-Arg-Gln-Pro-Arg-Gly-Trp-Glu-Gln-Leu, containing the recognition site for the protease furin, was incorporated between the toxin and the ligand to generate restrictocin-spacer-anti-TFR(scFv) and anti-TFR(scFv)-spacer-restrictocin. The incorporation of the proteolytically cleavable spacer enhanced the cell-killing activity of both constructs by 2-30-fold depending on the target cell line. However, the introduction of linker improved the cytotoxic activity only for anti-TFR(scFv)-linker-restrictocin. The proteolytically cleavable spacer-containing chimaeric toxins had similar cytotoxic activities irrespective of the location of the ligand on the toxin and they were found to release the restrictocin fragment efficiently on proteolysis in vitro.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10620501      PMCID: PMC1220753     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  39 in total

Review 1.  The Aspergillus ribonucleolytic toxins (ribotoxins).

Authors:  B Lamy; J Davies; D Schindler
Journal:  Targeted Diagn Ther       Date:  1992

Review 2.  Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis.

Authors:  Y Reiter; I Pastan
Journal:  Trends Biotechnol       Date:  1998-12       Impact factor: 19.536

3.  Effect of immunosuppressive agents on the immunogenicity and efficacy of an immunotoxin in mice.

Authors:  E E Gelber; E S Vitetta
Journal:  Clin Cancer Res       Date:  1998-05       Impact factor: 12.531

4.  Cytotoxic activity of ribonucleolytic toxin restrictocin-based chimeric toxins targeted to epidermal growth factor receptor.

Authors:  D Rathore; J K Batra
Journal:  FEBS Lett       Date:  1997-05-05       Impact factor: 4.124

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 6.  Immunotoxins for central nervous system malignancy.

Authors:  R J Youle
Journal:  Semin Cancer Biol       Date:  1996-04       Impact factor: 15.707

7.  Study of the interaction between the antitumour protein alpha-sarcin and phospholipid vesicles.

Authors:  M Gasset; A Martinez del Pozo; M Oñaderra; J G Gavilanes
Journal:  Biochem J       Date:  1989-03-01       Impact factor: 3.857

8.  Biologically active interleukin 2-ricin A chain fusion proteins may require intracellular proteolytic cleavage to exhibit a cytotoxic effect.

Authors:  J P Cook; P M Savage; J M Lord; L M Roberts
Journal:  Bioconjug Chem       Date:  1993 Nov-Dec       Impact factor: 4.774

9.  Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol.

Authors:  M Ogata; C M Fryling; I Pastan; D J FitzGerald
Journal:  J Biol Chem       Date:  1992-12-15       Impact factor: 5.486

10.  Furin activates Pseudomonas exotoxin A by specific cleavage in vivo and in vitro.

Authors:  N M Inocencio; J M Moehring; T J Moehring
Journal:  J Biol Chem       Date:  1994-12-16       Impact factor: 5.486

View more
  10 in total

Review 1.  Fusion protein linkers: property, design and functionality.

Authors:  Xiaoying Chen; Jennica L Zaro; Wei-Chiang Shen
Journal:  Adv Drug Deliv Rev       Date:  2012-09-29       Impact factor: 15.470

Review 2.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer.

Authors:  Tracy R Daniels; Ezequiel Bernabeu; José A Rodríguez; Shabnum Patel; Maggie Kozman; Diego A Chiappetta; Eggehard Holler; Julia Y Ljubimova; Gustavo Helguera; Manuel L Penichet
Journal:  Biochim Biophys Acta       Date:  2011-08-05

Review 3.  Designing immunotoxins for cancer therapy.

Authors:  Christopher A Pennell; Heidi A Erickson
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

4.  The distribution of saponins in vivo affects their synergy with chimeric toxins against tumours expressing human epidermal growth factor receptors in mice.

Authors:  C Bachran; A Weng; D Bachran; S B Riese; N Schellmann; M F Melzig; H Fuchs
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

5.  Efficient in vivo antitumor effect of an immunotoxin based on ribotoxin α-sarcin in nude mice bearing human colorectal cancer xenografts.

Authors:  Jaime Tomé-Amat; Miriam Olombrada; Javier Ruiz-de-la-Herrán; Eduardo Pérez-Gómez; Clara Andradas; Cristina Sánchez; Leopoldo Martínez; Álvaro Martínez-Del-Pozo; José G Gavilanes; Javier Lacadena
Journal:  Springerplus       Date:  2015-04-08

6.  Inclusion of a Furin Cleavage Site Enhances Antitumor Efficacy against Colorectal Cancer Cells of Ribotoxin α-Sarcin- or RNase T1-Based Immunotoxins.

Authors:  Javier Ruiz-de-la-Herrán; Jaime Tomé-Amat; Rodrigo Lázaro-Gorines; José G Gavilanes; Javier Lacadena
Journal:  Toxins (Basel)       Date:  2019-10-12       Impact factor: 4.546

7.  Viral Prefusion Targeting Using Entry Inhibitor Peptides: The Case of SARS-CoV-2 and Influenza A virus.

Authors:  Yasaman Behzadipour; Shiva Hemmati
Journal:  Int J Pept Res Ther       Date:  2022-01-03       Impact factor: 1.931

8.  Design and screening of a glial cell-specific, cell penetrating peptide for therapeutic applications in multiple sclerosis.

Authors:  Corey Heffernan; Huseyin Sumer; Gilles J Guillemin; Ursula Manuelpillai; Paul J Verma
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

9.  Anthrax toxin-mediated delivery of the Pseudomonas exotoxin A enzymatic domain to the cytosol of tumor cells via cleavable ubiquitin fusions.

Authors:  Christopher Bachran; Thomas Morley; Suzanne Abdelazim; Rasem J Fattah; Shihui Liu; Stephen H Leppla
Journal:  mBio       Date:  2013-04-30       Impact factor: 7.786

10.  A deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warhead.

Authors:  Tim D Jones; Arron R Hearn; Robert G E Holgate; Dorota Kozub; Mark H Fogg; Francis J Carr; Matthew P Baker; Javier Lacadena; Kurt R Gehlsen
Journal:  Protein Eng Des Sel       Date:  2016-11-01       Impact factor: 1.650

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.